🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523543-36-00
Completed Phase III

Study on the influence of FLUMAzenil regarding the incidence of pediatric emergence delirium (ED) in children undergoing ENT surgery – FLUMA Study

2025-523543-36-00 · tracked via the Priya Life Science EU tracker
Sponsor
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Sponsor type
Educational Institution
Therapeutic area
Not possible to specify
Decision date
23/01/2026
Enrollment target
1
Sites
Germany

Condition studied

pediatric emergence delirium

Investigational medicinal product(s)

SODIUM CHLORIDEFlumazenil B. Braun 01 mg/ml Injektionslösung und Konzentrat zur Herstellung einer Infusionslösung

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

The occurrence of postoperative delirium (pädED) until discharge from the recovery room. A score of ≥ 10 points is indicative of delirium.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523543-36-00 on CTIS ↗ ← All trials in the EU